Drugs / Neisseria lactamica
Neisseria lactamica
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04665791 | Mar → Oct 2021 | meningococcal meningitis | Center for Vaccine Development - Mali | Completed | No outcome recorded |
| — | NCT03549325 | Mar 2017 → Dec 2021 | meningococcal meningitis | University Hospital Southampton NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02249598 | Jul → Nov 2013 | — | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neisseria lactamica | “inoculating adult volunteers with Neisseria lactamica, a harmless 'cousin' of N. meningitidis, possibly prevents N. meningitidis carriage.” NCT02249598 ↗ |
| Known as | LyoNlac | “Nasally administered lyophilized Nlac (LyoNlac) might interrupt carriage and transmission of Nmen in sub-Saharan settings without requirement of a cold chain” PMID 41574175 ↗ Jan 2026 |
| Known as | N. lactamica | “Previously, researchers have given nose drops containing N. lactamica to over 400 volunteers” NCT04665791 ↗ |
| Known as | Nlac | “Nasally administered lyophilized Nlac (LyoNlac) might interrupt carriage and transmission of Nmen in sub-Saharan settings without requirement of a cold chain” PMID 41574175 ↗ Jan 20261“N. lactamica (Nlac) has been shown to be safe to use in human challenge experiments.” NCT03549325 ↗ |
| Known as | Y92-1009 | “reconstituted, lyophilized Nlac strain Y92-1009 (LyoNlac)” PMID 41574175 ↗ Jan 2026 |
| Modality | Other / unclassified | “N.lactamica bacteria” NCT02249598 ↗ |
| Route | Intranasal | “It will involve placing droplets of N.lactamica bacteria into the nose of half our group of volunteers” NCT02249598 ↗ |